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Signal transduction pathways that mediate C5a and
fMet-Leu-Phe (fMLP)-induced pertussis toxin (PTx)-sen-
sitive activation of phospholipase C (PLC) have been
investigated using a cotransfection assay system in
COS-7 cells. The abilities of the receptors for C5a and
fMLP to activate PLC b2 and PLC b3 through the Gbg
subunits of endogenous Gi proteins in COS-7 cells were
tested because both PLC b2 and PLC b3 were shown to
be activated by the bg subunits of G proteins in in vitro
reconstitution assays. Neither of the receptors can acti-
vate endogenous PLC b3 or recombinant PLC b3 in
transfected COS-7 cells. However, both receptors can
clearly activate PLC b2 in a PTx-sensitive manner, sug-
gesting that the receptors may interact with endoge-
nous PTx-sensitive G proteins and activate PLC b2 prob-
ably through the Gbg subunits. These findings were
further corroborated by the results that PLC b3 could
only be slightly activated by Gb1g1 or Gb1g5 in the co-
transfection assay, whereas the Gbg subunits strongly
activated PLC b2 under the same conditions. PLC b3 can
be activated by Gaq, Ga11, and Ga16 in the cotransfection
assay. In addition, the Gg2 and Gg3 mutants with substi-
tution of the C-terminal Cys residue by a Ser residue,
which can inhibit wild type Gbg-mediated activation of
PLC b2, were able to inhibit C5a or fMLP-mediated ac-
tivation of PLC b2. These Gg mutants, however, showed
little effect on m1-muscarinic receptor-mediated PLC
activation, which is mediated by the Gq class of G pro-
teins. These results all confirm that the Gbg subunits
are involved in PLC b2 activation by the two chemoat-
tractant receptors and suggest that in COS-7 cells acti-
vation of PLC b3 by Gbg may not be the primary path-
way for the receptors.
Heterotrimeric GTP-binding protein (G protein)1-mediated
signal transduction pathways are involved in a variety of bio-
logical processes, ranging from neuronal activities, metabo-
lism, hematopoietic functions, to some sensory processes (1–3).
These pathways can be divided into two groups based on their
sensitivities to Pertussis toxin (PTx). PTx is a bacterial toxin
that catalyzes ribosylation of C-terminal cysteine residues of
some Ga subunits, including the Gai subunits, Gao subunits,
and transducin a subunits. Modification by PTx prevents the
interaction between Ga subunits and receptors, thus blocking
ligand-mediated signal transduction (1, 4). The Ga subunits of
the Gq and Gs class of G proteins lack the C-terminal cysteine
residues; hence, signal transduction pathways mediated by
these Ga subunits are PTx-resistant (3).
Many G protein-coupled receptors transduce their signals
through the activation of phospholipase C (PLC). Some recep-
tors, such as the a1-adrenergic (5, 6) and m1-muscarinic cho-
linergic receptors (7), act mainly through the Gq class of G
proteins and are, thus, resistant to PTx treatment. Other re-
ceptors appear to activate PLC in a PTx-sensitive manner.
Typical examples are found in leukocytes, where responses to a
number of chemoattractants, including interleukin-8 (IL-8),
C5a, and f-Met-Leu-Phe (fMLP), are mostly PTx-sensitive (8–
16). A mechanism involved in the PTx-sensitive processes has
recently been proposed; ligand-bound receptors may interact
with PTx-sensitive G proteins, such as the Gi proteins, and
release Gbg, which then activates PLC. This hypothesis is
based on the findings that the Gbg subunits of G proteins can
activate certain isoforms of PLC b, while the Gai subunits
cannot. The Gbg subunits were shown to activate PLC b2 but
not PLC b1 or PLC b4 in a cotransfection assay (17–19) and
activate PLC b3 and PLC b2 in reconstitution assays with
purified proteins (20–25). Our previous report on reconstitu-
tion of PTx-sensitive, IL-8-induced activation of PLC b2 in
cotransfected COS-7 cells supports the hypothesis that the
chemokine receptor acts through Gbg activation of the PLC b2
isoform (26).
In this report, we investigated the signal transduction path-
ways for the C5a and fMLP receptors, which play important
roles in inflammation (8). C5a and fMLP receptors have previ-
ously been shown to couple selectively to PTx-insensitive Ga
subunit, Ga16 to activate PLC (27, 28). There must, however,
also be a distinct pathway that mediates the PTx-sensitive
responses to fMLP and C5a. The PTx-sensitive pathways may
be the predominant ones in mature leukocytes, because re-
sponses to chemoattractants were found to be largely PTx-
sensitive in these cells. Since C5a and fMLP, like IL-8, induce
Ca21 efflux and leukocyte chemotaxis that are sensitive to PTx
treatment, the C5a and fMLP receptors may utilize the same
signal transduction pathways as the IL-8 receptors (26). By
using the cotransfection assay, we found that these two recep-
tors can specifically activate PLC b2 but not PLC b3, presum-
ably through the Gbg subunits released from the Gi proteins.
The finding that the Gg2 and Gg3 mutants, with substitution of
the C-terminal Cys residues by Ser residues, can act as domi-
nant negative inhibitors to block Gbg-mediated activation of
PLC b2 in cotransfected COS-7 cells supports the notion that
the Gbg subunits are involved in the signal transduction proc-
esses of these chemoattractant receptors.
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MATERIALS AND METHODS
Cell Culture and Transfection—Cos-7 cells were cultured in Dulbec-
co’s modified Eagle’s medium containing 10% fetal calf serum under 5%
CO2 at 37 °C. For transfection, Cos-7 cells were seeded into 24-well
plates at a density of 1 3 105 cells/well the day before transfection
(32–34). The media were removed the next day, and 0.25 ml of Opti-
MEM (Life Technologies, Inc.) containing 2 ml of lipofectamine (Life
Technologies, Inc.) and 0.5 mg of plasmid DNA were added to each well.
Five hours later the transfection media were replaced by the culture
media. Then the cells were labeled with 10 mCi/ml myo[2-3H]inositol the
following day, and the levels of inositol phosphates were determined 1
day later as described previously (29). All the cDNAs used in these
studies were constructed into expression vectors that were driven by
the cytomegalovirus promoters (29).
SDS-Polyacrylamide Gel Electrophoresis and Western Blot—-For
Western analysis of protein expression in COS-7 cells, equal numbers of
cells were directly solubilized in SDS sample buffer. For analysis of Gg
expression, equal numbers of cells were incubated with phosphate-
buffered saline containing 1 mM EDTA for 5 min, and they were washed
off the plates and collected into microcentrifuge tubes. After brief spin-
ning, the cells were subjected to two freeze-thaw cycles in a hypotonic
buffer (10 mM Tris, pH 7.4) containing various protease inhibitors. Then
the cytosolic and particulate fractions were separated by high-speed
centrifugation. Finally the samples were solubilized in or diluted with
the SDS sample buffer and loaded to 12% SDS-polyacrylamide gels. The
proteins were subsequently electroblotted onto nitrocellulose mem-
branes and detected with antibodies indicated in the figure legends.
Construction of Gg Mutants—The Gg3CS mutant was generated by
polymerase chain reaction with the high fidelity DNA polymerase, pfu
(Stratagene), and the mutation was confirmed by DNA sequencing. The
Gg1CS and Gg2CS mutants were kindly provided by Dr. Narasimthan
Gautam from the Washington University, MO.
Ligand-binding Assays—-COS-7 cells in 24-well plates were cotrans-
fected with cDNAs encoding the receptors and various proteins includ-
ing PLCs, Gb, Gg, or b-galactosidase. Varying amounts of 125I-labeled
C5a (2200 Ci/mmol, DuPont NEN) were incubated with the transfec-
tants for 1 h on ice. Then the cells were washed three times with cold
phosphate-buffered saline containing 0.5% bovine serum albumin and
solubilized in 0.1 N sodium hydroxide. Aliquots were counted in a
g-counter. The values derived from cells transfected with the b-galac-
tosidase DNA were taken as nonspecific binding. The maximal ligand-
binding sites and affinities were determined by Scatchard analysis.
RESULTS
We used the cotransfection assay in COS-7 cells to charac-
terize signal transduction pathways that mediate PTx-sensi-
tive PLC activation by the receptors for C5a and fMLP. COS-7
cells transfected with the cDNA encoding the C5a receptor or
fMLP receptor alone showed no ligand-dependent accumula-
tion of IPs (Fig. 1), confirming the report that the C5a and
fMLP receptors do not couple to Gaq/11 (27) (COS-7 cells contain
endogenous Gaq/11 but not Ga16 (26)). However, when the cells
were cotransfected with the PLC b2 cDNA and the cDNA
encoding the C5a or fMLP receptor, there were marked ligand-
induced increases in accumulation of IPs, and these ligand-
induced responses were sensitive to PTx (Fig. 1). Cells cotrans-
fected with the cDNA encoding PLC b1 instead did not show
any ligand-induced responses (Fig. 1). Knowing that Gbg can
only activate PLC b2, but not PLC b1 in the cotransfection
system, and that COS-7 cells contain PLC b1, but not PLC b2
(17, 18), we interpret this result to conclude that the receptors
for C5a and fMLP may interact with endogenous PTx-sensitive
G proteins, presumably Gi2 proteins, and cause release of the
bg subunits, which activate the recombinant PLC b2. We as-
sume that the interaction is with Gi2 because only Gi2, but not
other known PTx-sensitive G proteins including the Gi1, Gi3, or
Go proteins, was detected in COS-7 cells (17).
Since COS-7 cells contain endogenous PLC b3 (18), we pre-
dict that the C5a or fMLP receptor would induce IP accumula-
tion by activating endogenous PLC b3 through Gbg. However,
this did not occur (Fig. 1), suggesting that the Gbg subunits
released from the endogenous Gi proteins were unable to acti-
vate the endogenous PLC b3. To investigate whether the C5a
or fMLP receptor can activate the recombinant PLC b3, we
cotransfected COS-7 cells with cDNAs encoding PLC b3 and
the C5a or fMLP receptor. No ligand-induced accumulation of
IPs was observed (Fig. 1), indicating that the receptors cannot
activate the recombinant PLC b3 either. To test whether the
recombinant PLC b3 can be activated by recombinant G pro-
tein subunits, we cotransfected COS-7 cells with cDNA encod-
ing b-galactosidase (as control), Gaq, Ga11, Ga16, Gb1g1, or
Gb1g5 and cDNA encoding PLC b3 as well as other PLC b
isoforms as controls. As shown in Fig. 2, the recombinant PLC
b3 as well as PLC b1 and b2 can all be activated by Gaq, Ga11,
or Ga16 (Fig. 2) as cells cotransfected with cDNAs encoding
PLC b and Gaq, Ga11, or Ga16 showed marked accumulation of
IPs over those transfected with PLC b or Ga alone. However,
Gb1g1 or Gb1g5 showed only weak activation of the recombi-
nant PLC b3, whereas the Gbg subunits markedly activated
the recombinant PLC b2 (Fig. 2). The Gbg subunits did not
activate PLC b1 or PLCb4 (Fig. 2), as we have demonstrated
previously (17–19). The weak activation of PLC b3 by Gbg may
explain why the C5a or fMLP receptors could not activate PLC
b3.
The expression levels of PLC b3 were determined. The levels
of the recombinant PLC b3 are at least 5-fold higher than those
of the endogenous PLC b3, and the levels of the recombinant
PLC b3 in various transfectants are rather constant (Fig. 2B).
The ligand-binding sites on cells expressing the C5a receptor
were also determined using 125I-labeled C5a. Cells coexpress-
ing the C5a receptor and b-galactosidase, PLC b3, or PLC b2
showed similar numbers of ligand-binding sites (300–375 fmol
per 1 3 105 cells) with affinities of 2.5–4 nM. Thus, the inabil-
ities of Gbg or the C5a receptor to activate PLC b3 were not the
result of variations in protein expression. Furthermore, we
compared the expression level of the recombinant PLC b3 with
that of PLC b2 in transfected COS cells. Dilutions of cell ex-
tracts from cells expressing recombinant PLC b2 or PLC b3,
together with dilutions of purified PLC b2 or b3 proteins with
defined protein concentrations, were analyzed by Western blot-
ting with antibodies specific to PLC b2 or b3. Based on the
signal intensities, we estimated that the expression levels of
FIG. 1. Specific activation of PLC b2 by C5a and fMLP recep-
tors. COS-7 cells were cotransfected with cDNA encoding PLC b1 (P1),
PLC b2 (P2), PLC b3 (P3), or b-galactosidase (LacZ) and cDNA encod-
ing the C5a (A) or fMLP (B) receptor. Ligand-induced accumulation of
inositol phosphates was determined 25 min after addition of ligand in
the presence or absence of PTx (500 ng/ml). PTx was added 4 h before
addition of ligand. 100 nM of C5a (A) and fMLP (B) were used in the
assay. The basal inositol phosphate levels in cells transfected with the
lacZ gene and with the PLC b1, b2, and b3 cDNAs are 700 6 57, 750 6
65, 1030 6 78, and 770 6 43 dpm, respectively.
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recombinant PLC b2 and PLC b3 in transfected COS-7 cells are
0.1–0.3 mg/105 cells (Fig. 2C). Therefore, it is reasonable to
conclude that Gbg is a poor activator for PLC b3 when com-
pared with PLC b2 in the cotransfection assay.
In order to obtain more evidence for involvement of Gbg in
C5a- or fMLP-mediated activation of PLC, we investigated
whether the Gg mutants, with substitution of the C-terminal
Cys residues by Ser residues, can act as dominant negative
mutants to inhibit Gbg-mediated PLC activation. The Gg1 and
Gg2 mutants, designated Gg1CS and Gg2CS, were found to be
able to bind to the Gb subunits and bring them into the cytosol
(30, 31). These Gg mutants, when paired with the Gb subunits,
failed to activate PLC b2 (17, 18), suggesting that the complex
of GgCS and Gb is nonfunctional. Recently, we introduced the
equivalent mutation into Gg3. The Gg3 mutant Gg3CS, like
Gg2CS and Gg1CS (17), cannot activate PLC b2 (Fig. 3A). How-
ever, Gg3CS differs from Gg1CS and Gg2CS in its ability to
associate with the particulate fractions; Gg3CS, unlike Gg1CS
and Gg2CS (17), can still associate with the particulate fraction
(Fig. 3B).
The cotransfection assay was used to test whether these Gg
mutants are capable of acting as dominant negative mutants to
inhibit Gbg-mediated effects. We found that cells cotransfected
with cDNAs encoding PLC b2, Gb1, Gg3, and Gg3CS showed
little accumulation of IPs compared with those cotransfected
with PLC b2, Gb1, and Gg3 (Fig. 3A), suggesting that Gg3CS
inhibited Gb1g3-mediated activation of PLC b2. To test
whether the Gg mutants can block ligand-mediated responses,
we cotransfected COS-7 cells with cDNAs encoding PLC b2, the
C5a receptor, and one of the Gg mutants. As shown in Fig. 4A,
Gg2CS and Gg3CS were capable of blocking C5a-mediated accu-
mulation of IPs, whereas the wild types and Gg1CS could not.
Knowing that COS-7 cells contain Gb1 and Gb2 (17) and that
Gg1CS cannot interact with Gb2 (30, 31), we interpreted the
Gg1CS results to suggest that Gg2CS and Gg3CS may be able to
scavenge most of the Gb subunits in the cells to prevent them
from activating PLC, whereas Gg1CS is unable to scavenge Gb2,
thus failing to inhibit C5a-mediated effects. We also deter-
mined the expression levels of PLC b2 and the numbers of
C5a-binding sites on cells expressing the C5a receptors. Coex-
pression of various Gg subunits did not significantly affect
C5a-binding sites on various transfectants (;350 fmol/1 3 105
cells) neither did it affect the expression levels of PLC b2 (Fig.
4C). Therefore, inhibition of Gbg- (Fig. 3A) and C5a (Fig. 4A)-
mediated PLC activation by the Gg22,3 mutants is unlikely to
result from changes in the expression levels of the proteins
involved in activation of PLC b2. The same result was also
observed for the fMLP receptor, i.e. the Gg2,3 mutants can
inhibit fMLP-mediated activation of PLCb2 in transfected
COS-7 cells (data not shown). In addition, it is interesting to
note that the Gg mutants did not appear to affect Ga-mediated
effector activation. In cotransfected COS-7 cells, Gg3CS (Fig.
4B) and Gg2CS (data not shown) did not inhibit m1-muscarinic
receptor-mediated activation of PLC, which is mediated by the
Ga subunits of the Gq class (7). Thus, the Gg mutants, Gg2CS
and Gg3CS, appear to only affect Gbg-mediated responses but
not Ga-mediated responses. In summary, these results support
FIG. 2. Activation of PLC b isoforms by G proteins. A, COS-7
cells were cotransfected with cDNAs encoding PLC b1 (P1), PLC b2
(P2), PLCb3 (P3), G protein subunits, and control plasmid b-galacto-
sidase (LacZ) as indicated in the figure. The next day cells were labeled
with [3H]inositol. One day later, the levels of inositol phosphates were
determined as described under “Materials and Methods.” B, COS-7 cells
were cotransfected with cDNAs encoding PLC b3 and the C5a receptor
(R), GaQ (q), Ga16 (16), or Gb1g5 (bg) or transfected with the b-galac-
tosidase DNA (Lz), as indicated in the figure. The cell extracts were
subjected to Western analysis 2 days after transfection with an anti-
body specific to PLC b3. C, COS-7 cells were transfected with LacZ (lane
1), PLC b2 (upper panel, lanes 2-4), or PLC b3 (lower panel, lanes 2–4),
and they were solubilized in the sample buffer 2 days after transfection.
Ten microliters (equivalent to 105 cells, lane 4), 3 ml (lane 3), and 1 ml
(lane 2) of cell extracts were loaded to a 7.5% SDS gel. The recombinant
PLC b2 (upper panel, lanes 5–7) and PLC b3 (lower panel, lanes 5–7)
proteins were purified from recombinant baculovirus expressing PLC
b2 and PLC b3, respectively. One microgram (lane 5), 0.3 mg (lane 6),
and 0.1 mg (lane 7) of the purified proteins were loaded to the SDS gel.
Then the proteins were electroblotted to a nitrocellulose membrane and
detected with antibodies specific to PLC b2 and PLC b3, respectively
(18).
FIG. 3. Characterization of the Gg3 mutant. A, inhibition of
Gb1g3-mediated activation of PLC b2 by Gg3CS. COS-7 cells were
cotransfected with cDNAs encoding PLC b2 and Gb1, Gg3, Gg3CS, or the
control b-galactosidase (LacZ) as indicated in the figure. The levels of
inositol phosphates were determined 2 days after transfection as de-
scribed under “Materials and Methods.” B, Western blot of Gg3CS.
COS-7 cells were transfected with the cDNA encoding Gg3, Gg3CS, or
the control LacZ. Two days after transfection the cells were separated
into the cytosolic and particulate fractions, which were then subjected
to Western analyses with an antibody specific to Gg3.
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the idea that the Gbg subunits mediate fMLP- and C5a-in-
duced activation of PLC b2.
DISCUSSION
In this report, we have demonstrated that the C5a and fMLP
receptors, like the IL-8 (18) and m2-muscarinic receptors (17),
can interact with PTx-sensitive G proteins (presumably Gi2)
causing the release of the Gbg subunits, which then specifically
activate PLC b2 in a PTx-sensitive manner. Although these
two receptors can also couple to Ga16, we believe that the
Gbg-mediated pathway may be the predominant one that oc-
curs in leukocytes, because the responses to these chemoattrac-
tants in mature leukocytes are mostly PTx-sensitive. Our re-
sults are also consistent with previous results demonstrating
that the C5a and fMLP receptors can interact with the Gi2
proteins (35–37).
Regulation of PLC b1, -b2, and -b4 by Gbg has been tested
before in the cotransfection assay (17–19), but here PLC b3 was
tested in this assay system for the first time. To our surprise,
PLC b3 can only be weakly activated by Gbg in the cotransfec-
tion assay system. Gbg was previously shown to activate PLC
b3 effectively in in vitro reconstitution assays with purified
proteins (23–25). In fact, there are other examples of apparent
specificity in the cellular system that are not seen in vitro. For
instance, Schultz and his co-workers (49, 50) have demon-
strated receptor-mediated specificity for G protein heterotrim-
ers that is not evident in the reconstitution system (23). There
are probably other factors, such as substrate compartmental-
ization, modification, and membrane interaction and the in-
volvement of accessory proteins, which may mediate specificity
in the cellular system. Nevertheless, the weak activation of
PLC b3 by Gbg explains the inabilities of the chemoattractant
receptors to activate endogenous or recombinant PLC b3 in
COS-7 cells and may explain the lack of significant PLC acti-
vation by non-Gq-coupling receptors in many systems where
PLC b3 is expressed. However, activation of PLC b3 by Gbg
may occur in vivo in cells where the expression levels of PLC b3
are higher than those of the recombinant in COS-7 cells or
where the subcellular localization of PLC b3 or production of
accessory proteins is differently regulated.
As we have demonstrated, the Gg mutants, Gg2CS and Gg3CS
in particular, can serve as dominant negative mutants to in-
hibit Gbg-mediated, but not Ga-mediated, activation of PLC.
This is presumably due to their abilities to form complexes with
all known Gb subunits. Although the Gg1CS and Gg2CS mu-
tants were demonstrated to be capable of binding to Gb (30,
31), we do not know whether the complexes of GgCS and Gb can
still interact with PLC b2. In other words, it is not clear
whether the changes in the Gg mutants impair the abilities of
the Gbg complexes to interact with PLC b2 or their abilities to
activate PLC b2. However, the ability of the Gg3CS mutant to
associate with the particulate fractions indicates that the lipid
modification on the Cys residue may not serve only as an
anchor for Gbg, but it may also have other functions. The lipid
modification at the C-terminal Cys residue may either partic-
ipate in effector activation or in orientation of the bg complexes
to allow better access of effectors to their substrates on the
membranes. It appears paradoxical that the Gg mutants had
no effect on m1-muscarinic receptor-mediated activation of PLC
because Gbg was shown to be essential for reconstitution of
m1-receptor-mediated activation of PLC in an in vitro system
using purified proteins (7, 38). We suggest two possible inter-
pretations. 1) There may still be interactions between receptors
and Ga subunits in the absence of Gbg depending on the nature
of receptors and G proteins, but Gbg may greatly facilitate the
interactions. In the COS-7 overexpression system, the require-
ment for Gbg may be overcome by the high expression levels of
a subunits and receptors. 2) The Gg mutants did not scavenge
all of the Gb subunits; hence, there may be enough normal Gbg
complexes present so that Ga-mediated activation of effectors
is largely unaffected. The result that more Gbg is required for
activation of PLC than Ga supports the second possibility (24,
39).
The GgCS mutants may not only inhibit Gbg-mediated acti-
vation of PLC, but they should also be able to block other
Gbg-mediated regulation of effectors, including adenylylcycla-
ses (23, 40), phosphatidylinositol 3-kinase (41), ion channels
(42, 43), mitogen-activated kinase (44), and b-adrenergic recep-
tor kinase (45, 46), etc. Therefore, the GgCS mutants, joined
with the other Gbg antagonists, including phosducin (47) and
the Gbg-binding region of b-adrenergic receptor kinase (48),
provide useful tools to test whether a specific G protein-coupled
signal pathway is mediated by Gbg in a variety of systems.
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